APLIN JOHN C 3

3 · ENDOCYTE INC · Filed Feb 4, 2011

Form 3

Period: 2011-02-04

Director

Holdings

Series C-1 Convertible Preferred Stock
(indirect: By CID Seed Fund, L.P.)
→ Common Stock (123,190 underlying)
Series C-3 Convertible Preferred Stock
(indirect: By CID Equity Capital VIII, L.P.)
→ Common Stock (41,855 underlying)
Series C-1 Convertible Preferred Stock
(indirect: By CID Equity Capital VIII, L.P.)
→ Common Stock (246,380 underlying)
Series C-3 Convertible Preferred Stock
(indirect: By CID Seed Fund, L.P.)
→ Common Stock (20,705 underlying)

Footnotes (4)

[F1]The reported securities are convertible at any time at the option of the reporting person, but automatically convert into shares of Common Stock on a 1-for-1 basis immediately prior to the closing of the Issuer's initial public offering.
[F2]Not applicable.
[F3]John Aplin is a Class A member of CID Equity Partners VIII, LLC, which has the ultimate voting and investment power over shares held of record by CID Equity Capital VIII, L.P., and he may be deemed to have voting and investment power over shares held of record by CID Equity Capital VIII, L.P. Mr. Aplin disclaims beneficial ownership of the shares directly held by the entities affiliated with CID except to the extent of his individual pecuniary interest therein.
[F4]John Aplin is a general partner of CID Seed Fund Partners I which has the ultimate voting and investment power over shares held of record by CID Seed Fund, L.P., and he may be deemed to have voting and investment power over shares held of record by CID Seed Fund, L.P. Mr. Aplin disclaims beneficial ownership of the shares directly held by the entities affiliated with CID except to the extent of his individual pecuniary interest therein.

Documents

2 files